{
    "clinical_study": {
        "@rank": "26691", 
        "arm_group": [
            {
                "arm_group_label": "CLG561, Concentration Level A", 
                "arm_group_type": "Experimental", 
                "description": "One intravitreal injection"
            }, 
            {
                "arm_group_label": "CLG561, Concentration Level B", 
                "arm_group_type": "Experimental", 
                "description": "One intravitreal injection"
            }, 
            {
                "arm_group_label": "CLG561, Concentration Level C", 
                "arm_group_type": "Experimental", 
                "description": "One intravitreal injection"
            }, 
            {
                "arm_group_label": "CLG561, Concentration Level D", 
                "arm_group_type": "Experimental", 
                "description": "One intravitreal injection"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety, tolerability, and serum\n      pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration."
        }, 
        "brief_title": "Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Age-related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": "Macular Degeneration"
        }, 
        "detailed_description": {
            "textblock": "Subjects will be divided into 4 cohorts, with the subjects in each cohort being administered\n      a single IVT dose of CLG561. Progress from one cohort to the next will be time-lagged to\n      allow for safety review. Dosing will also be time-lagged within each cohort. Only one eye\n      (designated as the study eye) will be dosed per subject. Post-dose safety assessments and\n      ocular examination will commence immediately after the IVT injection and continue throughout\n      the outpatient visits at pre-determined timepoints. Collection of post-injection blood\n      samples will also begin after the IVT injection at pre-determined timepoints."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of age-related macular degeneration in study eye, as specified in protocol.\n\n          -  Poor visual acuity in study eye, as specified in protocol.\n\n          -  Willing to receive meningitis and pneumonia vaccinations at least 2 weeks prior to\n             study treatment.\n\n          -  Females must be post-menopausal and/or surgically sterile.\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Treatments to the study eye within 28 days prior to study treatment, as specified in\n             protocol.\n\n          -  Any disease or medication expected to cause systemic or ocular immunosuppression.\n\n          -  Participation in another interventional clinical study or use of any experimental\n             treatment for AMD within 12 weeks prior to study treatment.\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01835015", 
            "org_study_id": "C-12-074"
        }, 
        "intervention": {
            "arm_group_label": [
                "CLG561, Concentration Level A", 
                "CLG561, Concentration Level B", 
                "CLG561, Concentration Level C", 
                "CLG561, Concentration Level D"
            ], 
            "description": "Administered by intravitreal injection, Day 1", 
            "intervention_name": "CLG561", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "First in human", 
            "Safety", 
            "Tolerability", 
            "Serum PK", 
            "Intravitreal (IVT)", 
            "Age-related macular degeneration", 
            "AMD", 
            "Geographic Atrophy", 
            "Choroidal neovascularization"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Susan Yanni, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "BCVA will be measured using Early Treatment Diabetic Retinopathy Study visual acuity charts", 
                "measure": "Change from Baseline in Best Corrected Visual Acuity (BCVA)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to Day 85"
            }, 
            {
                "description": "IOP will be measured by Goldmann applanation tonometry or tonopen, at the discretion of the Investigator.", 
                "measure": "Intra-Ocular Pressure (IOP)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "A dilated fundus examination will be performed to evaluate the health of the vitreous, retina, macula, choroid, and optic nerve", 
                "measure": "Change from Normal to Abnormal in Fundus Examination at Any Post-Therapy Visit as Compared to Baseline Assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to Day 85"
            }, 
            {
                "description": "A slit-lamp biomicroscopy examination will be performed to evaluate the anterior setment of the eye", 
                "measure": "Change from Normal to Abnormal in Ocular Signs at Any Post-Therapy Visit as Compared to Baseline Assessment", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, up to Day 85"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01835015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Area under the serum concentration-time curve from time zero to infinity [AUC(0-\u221e)]", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-tlast)]", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Area under the serum concentration-time curve from time zero to time \"t\" where t is a defined time point after administration [AUC(0-t)]", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Time to reach the maximum serum concentration after drug administration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Dose normalized observed maximum serum concentration following drug administration (Cmax/D)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Dose-normalized area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUC/D)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Terminal elimination half-life (T\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "The apparent volume of distribution during the terminal elimination phase following extravascular administration (Vz/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }, 
            {
                "description": "Contingent upon observed serum concentration levels", 
                "measure": "Apparent systemic (or total body) clearance from serum following extravascular administration (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to Day 85"
            }
        ], 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}